TR199902880T2 - Ince parçalanmis kristal budesonid parçaciklari içeren kompozisyon - Google Patents

Ince parçalanmis kristal budesonid parçaciklari içeren kompozisyon

Info

Publication number
TR199902880T2
TR199902880T2 TR1999/02880T TR9902880T TR199902880T2 TR 199902880 T2 TR199902880 T2 TR 199902880T2 TR 1999/02880 T TR1999/02880 T TR 1999/02880T TR 9902880 T TR9902880 T TR 9902880T TR 199902880 T2 TR199902880 T2 TR 199902880T2
Authority
TR
Turkey
Prior art keywords
particles
composition containing
finely divided
containing finely
divided crystalline
Prior art date
Application number
TR1999/02880T
Other languages
English (en)
Inventor
Bisrat Mikael
Moshashaee Saeed
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of TR199902880T2 publication Critical patent/TR199902880T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bulus, ince bölünmüs temel olarak kristal budesonid parçaciklari, ayirt edici özelligi temel olarak düzgündürler ve 1 ila 4.5m /g'lik bir BET degerine sahiptirler, onlari hazirlamak için islem, sözü edilen parçaciklari içeren farmasötik bir kompozisyon, sözü edilen parçaciklarin solunum bozuklugu tedavisinde kullanim için bir ilaç yapiminda kullanilmasi ve ihtiyaci olan bir hastaya sözü edilen parçaciklarin uygulanmasi ile solunum bozukluklarinin tedavisi için bir metod saglar.
TR1999/02880T 1997-05-23 1998-05-15 Ince parçalanmis kristal budesonid parçaciklari içeren kompozisyon TR199902880T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9701956A SE9701956D0 (sv) 1997-05-23 1997-05-23 New composition of matter

Publications (1)

Publication Number Publication Date
TR199902880T2 true TR199902880T2 (tr) 2000-02-21

Family

ID=20407079

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02880T TR199902880T2 (tr) 1997-05-23 1998-05-15 Ince parçalanmis kristal budesonid parçaciklari içeren kompozisyon

Country Status (28)

Country Link
US (2) US6346523B1 (tr)
EP (1) EP1005328B1 (tr)
JP (1) JP2001525850A (tr)
KR (1) KR100514971B1 (tr)
CN (1) CN1146406C (tr)
AR (1) AR015820A1 (tr)
AT (1) ATE246492T1 (tr)
AU (1) AU734763B2 (tr)
BR (1) BR9808812A (tr)
CA (1) CA2290538C (tr)
DE (1) DE69816997T2 (tr)
DK (1) DK1005328T3 (tr)
EE (1) EE03850B1 (tr)
ES (1) ES2205496T3 (tr)
HU (1) HUP0002212A3 (tr)
ID (1) ID24332A (tr)
IL (1) IL133098A (tr)
IS (1) IS5254A (tr)
NO (1) NO995540D0 (tr)
NZ (1) NZ500852A (tr)
PL (1) PL336902A1 (tr)
PT (1) PT1005328E (tr)
SE (1) SE9701956D0 (tr)
SK (1) SK158799A3 (tr)
TR (1) TR199902880T2 (tr)
TW (1) TW518236B (tr)
WO (1) WO1998052544A1 (tr)
ZA (1) ZA984127B (tr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4484247B2 (ja) * 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
CZ20023273A3 (cs) 2000-03-03 2003-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Zpracování materiálu opakovaným cyklem expanze a smrštění rozpouštědla
EP1354581A4 (en) * 2000-12-26 2007-07-04 Takeda Pharmaceutical POROUS SUBSTANCE AND METHOD FOR THE PRODUCTION THEREOF
GB0106403D0 (en) * 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
CA2456806C (en) 2001-08-08 2011-10-18 Brown University Research Foundation Methods for micronization of hydrophobic drugs
AU2002334935B2 (en) * 2001-10-10 2008-04-03 Boehringer Ingelheim Pharmaceuticals, Inc. Powder processing with pressurized gaseous fluids
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
EP1626742A1 (en) 2003-05-22 2006-02-22 Elan Pharma International Limited Sterilization of dispersions of nanoparticulate active agents with gamma radiation
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
WO2005088655A1 (en) * 2004-03-12 2005-09-22 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A magnetoresistive medium
WO2006096906A1 (en) * 2005-03-18 2006-09-21 Nanomaterials Technology Pte Ltd Inhalable drug
AU2006272438B2 (en) 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
EP1782839A1 (en) 2005-11-03 2007-05-09 Genetic S.p.A. Sterilization process of Glucocorticosteroid by supercritical CO2
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
JP2009526858A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー コルチコステロイド溶液を製造する方法
WO2008097664A1 (en) 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
US20100294986A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Supercritical fluid facilitated particle formation in microfluidic systems
US20100298602A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Systems and methods for microfluidic crystallization
EP2618818A4 (en) * 2010-09-22 2014-10-29 Map Pharmaceuticals Inc CORTICOSTEROID PARTICLES AND METHOD FOR PRODUCING THE SAME
CN102975731B (zh) * 2012-04-24 2015-08-12 南车南京浦镇车辆有限公司 轨道车辆司机室骨架与车体的安装结构
WO2021219230A1 (en) 2020-04-30 2021-11-04 Paolo Fiorina Antiviral treatment
KR102567655B1 (ko) 2020-11-13 2023-08-17 주식회사 비츠로이엠 진공커패시터 및 진공커패시터 제조 방법
KR102739398B1 (ko) 2021-11-17 2024-12-06 주식회사 비츠로이엠 가변형 진공 커패시터
KR102739399B1 (ko) 2021-11-17 2024-12-06 주식회사 비츠로이엠 가변형 진공 커패시터의 나선형 전극 위치 결정구조

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
AU624421B2 (en) 1988-10-05 1992-06-11 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
ES2078447T3 (es) 1990-06-15 1995-12-16 Merck & Co Inc Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales.
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
DK0613371T3 (da) * 1991-12-18 2002-05-13 Astrazeneca Ab Ny kombination af formoterol og budesonid
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles

Also Published As

Publication number Publication date
PT1005328E (pt) 2003-11-28
CN1257424A (zh) 2000-06-21
IS5254A (is) 1999-11-18
US20020037257A1 (en) 2002-03-28
WO1998052544A1 (en) 1998-11-26
KR100514971B1 (ko) 2005-09-15
US6346523B1 (en) 2002-02-12
CN1146406C (zh) 2004-04-21
US6468994B2 (en) 2002-10-22
NZ500852A (en) 2001-07-27
DE69816997T2 (de) 2004-07-22
ES2205496T3 (es) 2004-05-01
EP1005328A1 (en) 2000-06-07
ID24332A (id) 2000-07-13
DE69816997D1 (de) 2003-09-11
EE9900533A (et) 2000-06-15
HUP0002212A2 (hu) 2000-12-28
HUP0002212A3 (en) 2001-04-28
IL133098A0 (en) 2001-03-19
AU734763B2 (en) 2001-06-21
CA2290538C (en) 2007-01-02
AU7680098A (en) 1998-12-11
ATE246492T1 (de) 2003-08-15
IL133098A (en) 2005-03-20
NO995540L (no) 1999-11-12
TW518236B (en) 2003-01-21
ZA984127B (en) 1998-11-23
CA2290538A1 (en) 1998-11-26
NO995540D0 (no) 1999-11-12
JP2001525850A (ja) 2001-12-11
PL336902A1 (en) 2000-07-17
SK158799A3 (en) 2000-05-16
EE03850B1 (et) 2002-10-15
KR20010012821A (ko) 2001-02-26
DK1005328T3 (da) 2003-11-17
SE9701956D0 (sv) 1997-05-23
BR9808812A (pt) 2000-07-18
AR015820A1 (es) 2001-05-30
EP1005328B1 (en) 2003-08-06

Similar Documents

Publication Publication Date Title
TR199902880T2 (tr) Ince parçalanmis kristal budesonid parçaciklari içeren kompozisyon
NO934203D0 (no) Anvendelse av ioniske sl!ringspunktmodifiserende midler for } hindre partikkelaggregering under sterilisering
NO934271D0 (no) Anvendelse av rensede overflatemodifiseringsmidler for } hindre partikkelaggregering under sterilisering
EP0147761A3 (en) Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE69722023D1 (de) Eine neue kristalline polymorphe form von fluticasonepropionat, ein verfahren zu ihrer herstellung und pharmazeutische präparate davon
DE69738000D1 (de) Neue Arzneiformulierung enthaltend Budesonide
ATE133423T1 (de) Rekonstituierte hdl-teilchen und ihre verwendung
ATE320804T1 (de) Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme
ATA9487A (de) Bestaendiges mundpflegemittel in form freistehender einzeldosierungseinheiten und verfahren zum herstellen des mundpflegemittels
BE882833A (fr) Sels mixtes d'acides amines essentiels ou semi-essentiels et de leurs analogues exempts d'azote, en utilisant pour traiter des desordres renaux
ATE99932T1 (de) Verwendung von pyrrolicloncarbonsaeurealkylestern zur herstellung eines arzneimittels zur behandlung von ichtyosis.
FR2306939A1 (fr) Procede de purification et d'augmentation de la blancheur de minerais naturels de calcite
ATE257699T1 (de) Neuartige formulierung zur inhalation mit einer bulkdichte zwischen 0.28 und 0.38 g/ml, mit formoterol
FR2556348B1 (fr) Retinoides, leur preparation et leurs utilisations therapeutiques, notamment pour le traitement des neoplasies, de l'acne et du psoriasis
DE3478749D1 (en) Covalently bound heparin - antithrombin-iii complex, method for its preparation and its use for treating thromboembolism
ATE89728T1 (de) Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen.
FI915254A7 (fi) Tetrahydrofoolihaposta johdettuja diastereoisomeerisiä yhdisteitä, men etelmä niiden valmistamiseksi ja käyttö pelkistettyjen fosfaattien 6S- ja 6R-diastereoisomeerien synteesissä
IL130839A0 (en) New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml comprising terbutaline sulphate a process for preparing the formulation and the use thereof
EP0035597A3 (en) Pharmaceutical preparations
NO177598C (no) Fremgangsmåte for fremstilling av fine polymerpartikler med ensartet störrelse
GR3015132T3 (en) Novel ureas and thioureas, preparation thereof and application in therapy.
DE3584948D1 (de) Verwendung von micellaren partikeln zur herstellung von zusammensetzungen zum beschiessen von tumoren in menschen und deren verwendung.
FR2549726B1 (fr) Facteurs augmentant la formation d'anticorps humains et procede pour leur preparation
ATE40795T1 (de) Verwendung eines zerebral und peripher wirkenden antihypoxidotikums.
ATE68344T1 (de) Verwendung von spergualin oder eines seiner pharmazeutisch akzeptablen salze zur herstellung eines transplantation-immunitaet unterdrueckenden und anti-allergischen mittels.